FMP
Kindred Biosciences, Inc.
KIN
NASDAQ
Inactive Equity
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
9.25 USD
0.01000023 (0.108%)
About
ceo
Dr. Richard Chin
sector
Healthcare
industry
Drug Manufacturers - Specialty & Generic
website
http://www.kindredbio.com
exchange
NASDAQ
Description
Kindred Biosciences, Inc., a biopharmaceutical company, is developing biologics that focus on the lives of pets. The company has a pipeline of novel biologics in development across various therapeutic classes and intellectual property portfolio. Its programs under development include interleukin-31 and interleukin-4R for canine atopic dermatitis; KIND-030 for parvovirus in dogs; KIND-510a for the control of non-regenerative anemia in cats; anti-TNF antibody for inflammatory bowel disease in dogs; and other biologics candidates. The company was founded in 2012 and is headquartered in Burlingame, California.
CIK
0001561743
ISIN
US4945771099
CUSIP
494577109
Address
1555 Bayshore Hwy Ste 200
Phone
16507017901
Country
US
Employee
63
IPO Date
Dec 12, 2013
Key Executives
